Maynard Um
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $43 at Stifel
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Reiterated at Hold by Stifel After FDA Asks for More Info
-
-
-
-
-
-
-
KDIGO guidelines include FILSPARI for IgA nephropathy treatment
-
-
-
-
-
-
-
FDA cancels advisory committee for Travere's FILSPARI in rare kidney disease
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) call put ratio 1 call to 2.8 puts with a focus on June 15 and 17.50 puts
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)
-
399,518 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

